HER2-positive breast cancer with brain metastases: the decisions you may face
5 treatment settings, 4 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Limited brain metastases at first presentation
Stereotactic radiosurgery to each lesion, or surgery for a large symptomatic lesion, followed by HER2-directed systemic therapy; whole-brain radiotherapy reserved for many lesions.
A single very high dose, or a few doses, aimed at a small brain or spine target with millimetre precision, replacing whole-brain radiotherapy for most brain metastases.
- One to five sessions
- Spares healthy brain
- Treats targets surgery cannot reach
MRI uses a strong magnet and radio waves, with no ionising radiation, to picture soft tissue in finer contrast than CT, so it is the standard scan for brain tumours, prostate, rectal cancer staging, liver lesions and breast screening in high-risk women. It is slow, expensive and blurred by movement.
- No ionising radiation
- Best soft-tissue and brain imaging
- Functional sequences (diffusion, perfusion)
- One to three brain metastases: stereotactic radiosurgery alone versus radiosurgery plus whole-brain radiotherapy
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- Cognitive deterioration at 3 months 63.5% (SRS alone) vs 91.7% (SRS plus WBRT); no survival difference.
Cognitive deterioration at 3 months (%): Radiosurgery alone 63.5 (n=111) vs Radiosurgery plus whole-brain radiotherapy 91.7 (n=102)
- Limited to small targets
- Radiation necrosis in a minority
- Needs precise imaging and immobilisation
- Slow and expensive
- Motion artefacts
- Gadolinium concerns in renal impairment
- Between Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS) and MRI, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in Alliance N0574 (NCCTG N0574), and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (limited brain metastases at first presentation), which of the standard options do you recommend and why?Why: Guideline options include: Stereotactic radiosurgery to each lesion, or surgery for a large symptomatic lesion, followed by HER2-directed systemic therapy; whole-brain radiotherapy reserved for many lesions.
- How do the results of Alliance N0574 (NCCTG N0574) apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Active brain metastases after trastuzumab, pertuzumab and trastuzumab emtansine
Tucatinib with trastuzumab and capecitabine (HER2CLIMB), which improved survival and delayed brain progression.
A HER2-selective pill that works in the brain, for HER2-positive breast cancer with brain metastases.
The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable.
Capecitabine (Xeloda) is a tablet form of the chemotherapy fluorouracil. It is a backbone of treatment for bowel cancer and a standard option in advanced breast cancer.
- Tests Tucatinib, TrastuzumabHER2+ metastatic breast cancer after trastuzumab, pertuzumab, and T-DM1, including active brain metastases: tucatinib + trastuzumab + capecitabine vs placebo + trastuzumab + capecitabine
OS 21.9 vs 17.4 months, HR 0.66; CNS-PFS HR 0.32.
Progression-free survival (months): Tucatinib arm 7.8 (n=320) vs Placebo arm 5.6 (n=160) · HR 0.54 · source
- Reduce to 200 mg twice daily in severe impairment.
- Between Tucatinib, Trastuzumab and Capecitabine, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in HER2CLIMB, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (active brain metastases after trastuzumab, pertuzumab and trastuzumab emtansine), which of the standard options do you recommend and why?Why: Guideline options include: Tucatinib with trastuzumab and capecitabine (HER2CLIMB), which improved survival and delayed brain progression.
- Am I a candidate for Tucatinib, Trastuzumab, Capecitabine, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of HER2CLIMB apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Brain metastases, stable or active, second line
Trastuzumab deruxtecan, with intracranial responses in most patients (DESTINY-Breast12), positioned as second-line therapy after DESTINY-Breast03.
Trastuzumab deruxtecan (Enhertu) is the most successful ADC ever. It redefined HER2 by working in tumours with only tiny amounts of the protein, and in 2026 moved into early-stage breast cancer.
- Tests Trastuzumab deruxtecanHER2+ metastatic breast cancer with or without brain metastases: single-arm T-DXd
CNS ORR 71.7%; 12-month PFS 61.6% in brain-metastasis cohort.
- Tests Trastuzumab deruxtecanHER2+ metastatic breast cancer after trastuzumab and taxane: T-DXd vs T-DM1
PFS HR 0.33; OS HR 0.64.
Progression-free survival (BICR) (months): Trastuzumab deruxtecan 28.8 (n=261) vs Trastuzumab emtansine 6.8 (n=263) · HR 0.33 · source
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 18% |
| Nausea · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 7% |
| Anaemia · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 7% |
| Fatigue · DESTINY-Breast03/04; all-grade rates ≥20% per label | - | 6% |
- Interstitial lung disease in 10-15%: hold for any respiratory symptom and image; permanently discontinue for grade 2 or above. Moderately emetogenic: three-drug prophylaxis.
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- Is Trastuzumab deruxtecan the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?Why: A single standard does not mean a single choice; timing and trials are decisions too.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in DESTINY-Breast12 and DESTINY-Breast03, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- Which side effects of Trastuzumab deruxtecan are most likely for me, which are reversible, and which would make us stop?Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (brain metastases, stable or active, second line), which of the standard options do you recommend and why?Why: Guideline options include: Trastuzumab deruxtecan, with intracranial responses in most patients (DESTINY-Breast12), positioned as second-line therapy after DESTINY-Breast03.
- Am I a candidate for Trastuzumab deruxtecan, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of DESTINY-Breast12 and DESTINY-Breast03 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
First-line maintenance to delay brain progression
Tucatinib added to trastuzumab and pertuzumab maintenance after induction chemotherapy (HER2CLIMB-05).
A HER2-selective pill that works in the brain, for HER2-positive breast cancer with brain metastases.
The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable.
A second HER2 antibody that binds a different spot from trastuzumab, blocking HER2 from pairing with HER3; together they extended survival by 16 months in CLEOPATRA.
- First-line HER2+ metastatic breast cancer after induction with taxane + trastuzumab + pertuzumab: maintenance tucatinib + HP vs placebo + HP
PFS 24.9 vs 16.3 months, HR 0.64.
Progression-free survival (months): Tucatinib + trastuzumab + pertuzumab 24.9 vs Placebo + trastuzumab + pertuzumab 16.3 · HR 0.641 · source
- Reduce to 200 mg twice daily in severe impairment.
- Between Tucatinib, Trastuzumab and Pertuzumab, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in HER2CLIMB-05, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (first-line maintenance to delay brain progression), which of the standard options do you recommend and why?Why: Guideline options include: Tucatinib added to trastuzumab and pertuzumab maintenance after induction chemotherapy (HER2CLIMB-05).
- Am I a candidate for Tucatinib, Trastuzumab, Pertuzumab, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of HER2CLIMB-05 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Later lines
Neratinib or lapatinib with capecitabine, trastuzumab emtansine with tucatinib (HER2CLIMB-02), repeat radiosurgery, or a clinical trial.
A pill taken for a year after trastuzumab to further reduce recurrence in HER2-positive, hormone-positive breast cancer, limited by severe diarrhoea.
Lapatinib was the first HER2-blocking pill (2007) and is now mostly a comparator arm and a late-line option, displaced by tucatinib and ADCs.
Capecitabine (Xeloda) is a tablet form of the chemotherapy fluorouracil. It is a backbone of treatment for bowel cancer and a standard option in advanced breast cancer.
Trastuzumab emtansine (Kadcyla, T-DM1) was the first ADC for a solid tumour (2013). It is still standard after surgery for HER2+ breast cancer patients whose tumour did not fully respond to pre-surgery treatment.
- Tests Trastuzumab emtansineHER2+ metastatic breast cancer after trastuzumab and taxane: tucatinib + T-DM1 vs placebo + T-DM1
PFS 9.5 vs 7.4 months, HR 0.76; OS no benefit.
- Take with food. Loperamide prophylaxis from the first dose for diarrhoea.
- Take at least 1 hour before or after food; a high-fat meal raises exposure over fourfold. Avoid grapefruit.
- Known QT prolongation. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.
- Reduce to 750 mg daily in severe impairment; hepatotoxicity is a boxed warning.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Thrombocytopenia · KATHERINE (adjuvant) | 29% | 6% |
| Fatigue · KATHERINE (adjuvant) | 50% | - |
| Nausea · KATHERINE (adjuvant) | 42% | - |
| Transaminases increased · KATHERINE (adjuvant) | 32% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- Between Neratinib, Lapatinib, Capecitabine and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in HER2CLIMB-02, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- Which side effects of Trastuzumab emtansine are most likely for me, which are reversible, and which would make us stop?Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (later lines), which of the standard options do you recommend and why?Why: Guideline options include: Neratinib or lapatinib with capecitabine, trastuzumab emtansine with tucatinib (HER2CLIMB-02), repeat radiosurgery, or a clinical trial.
- Am I a candidate for Neratinib, Lapatinib, Capecitabine or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of HER2CLIMB-02 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.